A kind of doxorubicin nanometer drug-carrying system, its preparation method and its application

Abstract

The invention discloses an adriamycin nano drug delivery system as well as a preparation method and application thereof. The drug delivery system comprises the following components in percentage by weight: 0.02%-1.5% of active ingredient containing adriamycin, 1%-20% of solid lipid, 0.1%-20% of liquid lipid, 0.5%-20% of emulsifier and 0.1%-5% of isoosmotic adjusting agent, wherein the solid lipid and the liquid lipid form nanoparticles to cover the active ingredient containing the adriamycin. The preparation method comprises the following steps: (1), uniformly dispersing the active ingredient containing the adriamycin, the solid lipid, the liquid lipid and fat-soluble emulsifier in an organic solvent, evaporating the organic solvent to obtain an oil phase; (2), uniformly dispersing other emulsifiers and the isoosmotic adjusting agent in water to obtain a water phase; (3), adding the water phase into the oil phase for emulsifying drop by drop; (4), homogenizing under high pressure; (5), cooling and degerming. The adriamycin nano drug delivery system disclosed by the invention can be used for realizing co-transporting of the adriamycin and a chemosensitizer, so that the killability of the adriamycin on liver cancer cells is strengthened.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and more specifically relates to a nano drug-carrying system, its preparation method and application. Background technique [0002] Primary hepatocellular carcinoma is a major disease that seriously endangers human health. It is highly malignant, invades and grows rapidly, and is easy to relapse after treatment. The 5-year survival rate is less than 5%. It is called "the king of cancers". At present, chemotherapy drugs for the treatment of primary liver cancer include doxorubicin, 5-fluorouracil, cisplatin, mitomycin, camptothecin, gemcitabine, sorafenib, etc. Clinical standard medication. However, liver cancer cells usually have primary drug resistance, and most liver cancers occur on the basis of existing liver diseases, which affect the absorption and metabolism of drugs, making the therapeutic effect of single chemotherapy drugs limited. Therefore, the current focus of research on anti-liv...

AI Technical Summary

Problems solved by technology

However, the above-mentioned combined drug uses different preparations of the two active ingredients in combination, and does not use the same carrier for drug co-delivery, so there are two different active ingredients (different chemotherapeutic drugs, sensitizers and chemotherapeutic drugs) in vivo pharmacokinetics However, due to the inconsistency of biological behavior, the inability of the two active ingredients to be delivered to tumor cells at the same time, and the low bioavailability of the drug, its therapeutic effect is still limited.

Images